• Home
  • News
  • Extended-release, abuse-deterrent opioid safe, effective for chronic low back pain

Extended-release, abuse-deterrent opioid safe, effective for chronic low back pain

December 07, 2017 12:49 PM | Deleted user
December 6, 2017

Egalet Corporation recently announced that Egalet-002, an extended-release, abuse-deterrent form of oxycodone, demonstrated safety and efficacy endpoints for the treatment of moderate-to-severe chronic low back pain in a phase 3 trial.

The multicenter, double-blind, enriched enrollment, randomized withdrawal study evaluated how safe and effective Egalet-002 was in opioid-experienced and opioid-naïve patients with moderate-to-severe chronic low back pain compared with placebo.

The results showed that average pain intensity from randomization to week 16 was statistically and significantly different among patients with receiving Egalet-002 vs. placebo.

In a previous safety study of Egalet-002, the drug was found to be generally well-tolerated for up to 56 weeks in opioid-experienced patients with moderate-to-severe chronic noncancer pain.

The current study did not identify any new safety concerns.

“These results demonstrate Egalet-002, an abuse-deterrent, extended-release oxycodone, provided effective pain relief for patients with moderate-to-severe chronic back pain,” Bob Radiepresident and CEO of Egalet, said in a press release. “Given the prevalence of chronic back pain combined with the prescription abuse epidemic, we believe development of more abuse-deterrent products like Egalet-002 is important for our communities.”

Disclosure:  Healio Internal Medicine was unable to confirm relevant financial disclosures at the time of publication.


Contact WISAM

563 Carter Court, Suite B
Kimberly, WI 54136
WISAM@badgerbay.co

Donate Today!

Help fund WISAM
WISAM is funded in part by generous donations from patrons such as yourself.  Click here to make your donation today.  Your donation is tax deductable.


Copyright © 2018 WISAM All rights reserved.  | Terms of Use | Privacy Policy

Powered by Wild Apricot Membership Software